Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?

This clinical-stage biotech advancing precision medicines reported a notable insider sale amid strong one-year share ...

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision ...

Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials

This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale.
Average Socialite on MSN

The Maze open house, NYC

Download our Free App & Subscribe to our Newsletter for More NYC EventsDeets: The Maze NYC, NYC’s First Alcohol-Free Members Club, is hosting an open evening for those curious about The Maze - a ...

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
Business Wire

Maze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a Potential Treatment for APOL1 Kidney Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the initiation of dosing in the company’s Phase 1 ...